Illumina’s MiSeq Leads Next-Generation Systems, Kalorama Information Survey Finds

Illumina has the most prevalent model of sequencer in a worldwide survey of labs performing sequencing, according to a recent Kalorama Information survey. The healthcare market research publisher said Illumina’s MiSeq is the most popular individual sequencer model, though Life Technologies’ systems of all models are still the most commonly found in labs overall.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Illumina has momentum, the most popular model and clearly leads next gen. HiSeq sequencers of all models are collectively even more common than the MiSeq, which further illustrates Illumina’s market position.

New York, NY (PRWEB) September 16, 2013

Illumina has the most prevalent model of sequencer in a worldwide survey of labs performing sequencing, according to a recent Kalorama Information survey. The healthcare market research publisher said Illumina’s MiSeq is the most popular individual sequencer model, though Life Technologies’ systems of all models are still the most commonly found in labs overall. The finding was made in a new report, “Next Generation Sequencing Trends”, which is based on a telephone survey of 110 labs performing sequencing.

The MiSeq Personal Sequencer system, launched by Illumina in 2011, made surprisingly fast inroads according to the survey, and represents 14.8% of systems in the labs surveyed, edging out Life Technologies’ Sanger sequencing model 3730xl with 12.8% of systems in labs surveyed. Illumina also has the second most commonly owned next generation sequencer, the HiSeq 2000, which comprises 12% of the systems found in the labs. Illumina’s HiSeq 2500 and Life’s Ion Torrent PGM are tied for third in terms of most commonly owned, with 10% of systems.

“Illumina has momentum, the most popular model and clearly leads next gen,” said Justin Saeks, the report’s author. “HiSeq sequencers of all models are collectively even more common than the MiSeq, which further illustrates Illumina’s market position.”

HiSeq and MiSeq systems are also the most likely to be considered for future purchase plans, as well as plans for future clinical diagnostic and clinical research usage. Despite the good news for Illumina, the survey found that Life Technologies/ Applied Biosystems equipment has a large presence in the labs surveyed because of multiple system ownership. The report found that dual ownership is common, and most labs with a next-generation sequencer still have at least one Life Technologies/ Applied Biosystems capillary system as well.

“Three quarters of MiSeq owners also own and use a capillary sequencer,” said Saeks.

The report finds that the median number of sequencers of all types owned in the labs surveyed is three, and for NGS systems the median number of sequencers is two. Some brands seem to be used together more or less often in labs, and the report notes this. For instance, MiSeq systems are less common relative to the individual HiSeq models in the labs owning ABI/ Life Technologies NGS systems; and these labs are the least likely to have a capillary system. More complimentary systems data is provided in the report.

The report, “Next Generation Sequencing Trends”, provides model ownership statistics, cross-ownership data by brand, information on common applications, regional ownership data and more. The report is based on a telephone consultation of 110 laboratories which was carried out from April to June of 2013, with the majority in the latter portion. The survey effort targeted labs likely to be doing, or likely to be planning, applications of sequencing in either diagnostic or clinical research settings. More information can be found at http://www.kaloramainformation.com/Generation-Sequencing-Trends-7702505/.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn